CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles.
Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤治疗领域的不断演变,尤其是在多发性骨髓瘤免疫治疗方面,为医疗提供者,尤其是护士,带来了新的挑战和机遇。嵌合抗原受体(CAR)T细胞疗法和双特异性抗体等创新疗法已经彻底改变了复发/难治性多发性骨髓瘤患者的护理。
本文强调护士在管理护理过渡中的作用,着重指出其在患者教育、护理协调以及治疗阶段之间无缝交接方面的职责。
通过对现有文献的回顾以及从专家意见和经验中获得的知识,本文为管理护理过渡的护士提出了建议。
有效的医疗过渡可优化患者结局,减少获取障碍,并确保接受CAR-T 细胞疗法和双特异性抗体等复杂治疗的患者获得连续性照护。这些疗法在医疗过渡期间需要精细的协调。
The evolving landscape of oncology treatment, particularly in the realm of multiple myeloma immunotherapy, presents new challenges and opportunities for healthcare providers and, of note, nurses. Innovative treatments like chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have revolutionized care for patients with relapsed and refractory multiple myeloma.
This article underscores the role of nurses in managing care transitions, emphasizing their responsibilities in patient education, coordination of care, and the seamless handoff between treatment phases.
Through a review of existing literature and knowledge gained from expert opinions and experiences, this article presents recommendations for nurses managing care transitions.
Effective transitions of care optimize patient outcomes, minimize barriers to access, and ensure continuity of care for patients undergoing complex treatments like CAR T-cell therapy and bispecific antibodies. These therapies require meticulous coordination during transitions of care.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。